Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)

Study identifier:D8850C00019

ClinicalTrials.gov identifier:NCT05687877

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

General Drug Use-Result study of Evusheld Intramuscular Injection Set (Treatment and Prevention of Symptomatic Disease caused by SARS-CoV-2 Infection)

Medical condition

SARS-CoV-2 infection

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

700

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 06 Jan 2023
Estimated Primary Completion Date: 31 Mar 2026
Estimated Study Completion Date: 31 Mar 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria